Defunct Company
Total Trials
17
As Lead Sponsor
As Collaborator
0
Total Enrollment
3,226
NCT00452179
Safety and Efficacy Study of APD125 in Patient With Insomnia
Phase: Phase 2
Role: Lead Sponsor
Start: Feb 28, 2007
Completion: Jun 30, 2007
NCT00529646
Single-Dose Safety Study of APD791 in Healthy Volunteers
Phase: Phase 1
Start: Jul 31, 2007
Completion: Not specified
NCT00619931
A Multiple-Dose Study to Assess the Safety, Tolerability, and Steady State Pharmacokinetics of APD791 in Healthy Volunteers
Start: Jan 31, 2008
Completion: Jun 30, 2008
NCT00664664
Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia
Start: Apr 30, 2008
Completion: Nov 30, 2008
NCT01093508
Single-dose Safety Study of APD916 in Healthy Volunteers
Start: Mar 31, 2010
Completion: Jul 31, 2010
NCT02044874
A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation
Start: Mar 31, 2014
Completion: Nov 30, 2014
NCT02447302
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis
Start: Oct 15, 2015
Completion: Feb 14, 2018
NCT02536404
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis
Start: Jan 25, 2016
Completion: Nov 1, 2018
NCT03072953
Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum
Start: Jun 7, 2017
Completion: May 22, 2018
NCT03139032
Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
Start: Jul 17, 2017
Completion: Dec 6, 2017
NCT03155945
Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain
Start: Jul 19, 2017
Completion: Sep 10, 2018
NCT03155932
Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis
Start: Dec 29, 2017
Completion: Jan 31, 2019
NCT03945188
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Phase: Phase 3
Start: Jun 13, 2019
Completion: Feb 16, 2022
NCT04043455
Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)
Start: Jul 24, 2019
Completion: Apr 29, 2021
NCT04162769
A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
Start: Oct 4, 2019
Completion: Oct 11, 2021
NCT03996369
Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis
Start: Sep 15, 2020
Completion: Dec 7, 2021
NCT04655599
Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
Start: Jan 29, 2021
Completion: Apr 13, 2021